ASH 2022 | AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML

Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, shares insights into the results of the UK NCRI AML19 trial (ISRCTN78449203), which assessed the use of gemtuzumab ozogamicin (GO) in combination with FLAG-Ida or daunorubicin-araC (DA) plus etoposide in patients with standard-risk acute myeloid leukemia (AML), and FLAG-Ida versus CPX-351 in patients with high-risk AML. In patients with standard-risk AML, the trial showed a benefit for the combination of GO and FLAG-Ida in terms of relapse risk, and demonstrated a survival benefit in patients with NPM1 and FLT3-mutated AML. In high-risk patients, the trial showed a benefit in relapse-free survival (RFS) in the CPX-351 arm. In addition, patients with secondary AML gene mutations particularly benefited from CPX-351. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.